We identified 126 tumor cell lines established from patients with small cell cancer at the NCI-Navy Medical Oncology Branch from 1977 through 1992. Extensive clinical information was available on 96 patients from whom these cell lines were established. These patients comprised approximately one fourth of the 407 patients treated on prospective therapeutic clinical trials during the same time period. The proportion of tumor cell lines established from previously untreated patients with both limited and extensive stage small cell lung cancer increased during the 16 years of the study (P = 0.008). MYCfamily DNA amplification was present in 16 of 44 (36%) tumor cell lines established from previously treated patients compared to 7 of 52 (1 1%) of tumor cell lines established from untreated patients (P = 0.009). MYC DNA amplification in tumor cell lines established from patients previously treated with chemotherapy continued to be associated with shortened survival (P = 0.001 ). The initiation of a policy to obtain tumor tissue for the purpose of selecting chemotherapeutic agents given to individual patients was associated with an increase in the proportion of patients from whom tumor cell lines could be established for both extensive and limited stage patients (P = 0.0001 and 0.05, respectively). D 1996 wiley-Liss, Inc.Key words: lung neoplasms, oncogenes, drug therapy, mortality, pathologyThree of the members of the MYC family, MYC, NMYC, and LMYC, have been shown to be amplified in tumors and tumor cell lines from patients with small cell lung cancer [l-181. MYC DNA amplification has been the most frequently observed and is associated with a variant form of small cell lung cancer cell lines that have a more rapid growth rate than the classic type [2,19,201. We have previously shown that MYC family DNA amplification is more common in tumors and tumor cell lines derived from small cell lung cancer patients previously treated with combination chemotherapy [7,10,14,21]. established from chemotherapy-treated patients is associated with a shortened survival time [7,141. This supplement has attempted to provide a comprehensive list of all cell lines established at the NCI-Navy and NCI-VA Medical Oncology Branches. We have collected extensive clinical information on nearly all the patients with small cell lung cancer from whom cell lines were established. However, many of our cell lines have appeared in the literature (and included in this supplement) which have not been part of our analysis of MYC family DNA amplification and its association with small cell lung cancer patients' clinical status and course. Tumor cell lines established from patients treated on prospective clinical protocols and patients who have comprehensive data about their treatment have been included in this patient treatment analysis. Patients from whom tumor cell lines were established but not included in this analysis have footnotes explaining why they have been excluded. In addition, we have included references from our previous article...
In small cell lung carcinoma, one of the short arms of chromosome 3 is typically lost. To investigate chromosome 3 in extrapulmonary small cell carcinoma, we used DNA probes that detect restriction-fragment-length polymorphisms at loci on 3p. These probes were used to study DNA extracted from tumors and normal tissues and/or tumor cell lines from five patients with extrapulmonary small cell cancer. Tumor DNA from four of the five patients with extrapulmonary small cell cancer retained heterozygosity at loci on 3p. Cytogenetic studies of the tumor cell lines established from these four patients showed retention of both short arms of chromosome 3. We conclude that the loss of genetic material from 3p observed in small cell lung cancer is not typical in extrapulmonary small cell cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.